Provectus Pharmaceuticals, Inc.(OTC: PVCT) is a small-cap pharmaceutical company focused on developing treatments for oncology and dermatology. Shares of PVCT have started to gain some momentum the past few weeks in anticipation of clinical data that is being presented in November.
The data comes from its Phase 2 study of PV-10 in metastatic melanoma. This will be presented at the 7th International Melanoma Research Congress in Sydney, Australia, on November 4, 2010 at 4:30 p.m.PVCT will be presenting efficacy data on the full study population, which will include response rate, progression-free-survival and overall survival. These are very important numbers for the future of PVCT and PV-10. At ASCO 2010, they presented data on the “first 40 subjects in its Phase 2 clinical trial of PV-10 for metastatic melanoma, with an objective response ("OR") observed in 61% of subjects and a mean Progression Free Survival ("PFS") of at least 11.1 months among those subjects achieving an OR.” Agarwala has previously said that PV-10 could play an important part in the management/treatment of melanoma because of the efficacy it has shown in early and late stages of melanoma. It's also noteworthy that PV-10 has demonstrated a very benign safety profile, with no serious adverse events either.
PV-10 is an interesting molecule whose immunological mechanism will be studied in a Phase 2 study to provide additional evidence of PV-10’s bystander effect. It is currently a part of the FDA’s Compassionate Use Program which provides experimental therapeutics to patients prior to final FDA approval. Provectus is also exploring the use of PV-10 in liver(currently in Phase 1) and breast cancer(completed Phase 1). Provectus is planning for a Phase 2 study of PV-10 for recurrent breast cancer.
No comments:
Post a Comment